Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

36.80USD
23 Apr 2018
Change (% chg)

$0.17 (+0.46%)
Prev Close
$36.63
Open
$36.67
Day's High
$36.89
Day's Low
$36.60
Volume
24,080,746
Avg. Vol
22,434,884
52-wk High
$39.43
52-wk Low
$31.67

Latest Key Developments (Source: Significant Developments)

IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending Disclosure
Wednesday, 18 Apr 2018 06:12am EDT 

April 18 (Reuters) - Pfizer Inc ::INTERNATIONAL BROTHERHOOD OF TEAMSTERS - URGES PFIZER SHAREHOLDERS TO VOTE FOR PROPOSAL 7 FOR CORPORATE POLITICAL SPENDING DISCLOSURE.  Full Article

Pfizer Will Relocate Its Global Headquarters From 235 East 42nd Street To Spiral
Tuesday, 10 Apr 2018 08:30am EDT 

April 10 (Reuters) - Pfizer Inc ::PFIZER SIGNS LEASE FOR THE SPIRAL AT HUDSON YARDS IN MANHATTAN.CURRENTLY IN PROCESS OF SELLING ITS HEADQUARTERS PROPERTY ON EAST 42(ND) STREET.PFIZER INC - AS PART OF 20-YEAR LEASE AGREEMENT, PFIZER WILL RELOCATE ITS GLOBAL HEADQUARTERS FROM 235 EAST 42ND STREET TO SPIRAL.YEAR LEASE FOR SPIRAL, AN OFFICE TOWER BEING BUILT BY TISHMAN SPEYER, AT 66 HUDSON BOULEVARD AT HUDSON YARDS OF MANHATTAN.  Full Article

Pfizer and Allogene enter into agreement for Pfizer's CAR T cell therapy
Tuesday, 3 Apr 2018 08:00am EDT 

April 3 (Reuters) - Pfizer Inc ::SAYS CO AND ALLOGENE THERAPEUTICS ENTER INTO ASSET CONTRIBUTION AGREEMENT FOR PFIZER’S ALLOGENEIC CAR T IMMUNO-­ONCOLOGY PORTFOLIO.SAYS AGREEMENT AIMS TO ACCELERATE THE DEVELOPMENT OF PFIZER'S CAR T CELL THERAPY.SAYS ALLOGENE WILL RECEIVE RIGHTS FROM CO TO 16 PRE-CLINICAL CAR T ASSETS LICENSED FROM CELLECTIS AND SERVIER.SAYS ALLOGENE WILL RECEIVE RIGHTS TO ONE CLINICAL ASSET FROM SERVIER CALLED UCART19.SAYS CO WILL HOLD 25 PERCENT STAKE IN ALLOGENE THERAPEUTICS; CO WILL BE REPRESENTED ON ALLOGENE'S BOARD.  Full Article

GSK did not put in final bid for Pfizer consumer unit - source
Friday, 23 Mar 2018 06:13am EDT 

March 23 (Reuters) - Glaxosmithkline Plc GSK.L::GLAXOSMITHKLINE DID NOT PUT IN A FINAL BID FOR PFIZER'S CONSUMER HEALTHCARE UNIT - SOURCE FAMILIAR WITH SITUATION.  Full Article

Pfizer says continues to evaluate options for consumer health
Friday, 23 Mar 2018 04:54am EDT 

March 23 (Reuters) - Pfizer Inc ::PFIZER SAYS CONTINUES TO EVALUATE POTENTIAL STRATEGIC ALTERNATIVES FOR THE CONSUMER HEALTHCARE BUSINESS, INCLUDING A SPIN-OFF,SALE OR OTHER TRANSACTION, AND PFIZER ULTIMATELY RETAINING THE BUSINESS..PFIZER SAYS HAS NOT YET MADE A DECISION, BUT CONTINUES TO EXPECT ONE IN 2018.  Full Article

GlaxoSmithKline Withdraws From Process Relating To Pfizer's Consumer Healthcare Business​
Friday, 23 Mar 2018 03:44am EDT 

March 23 (Reuters) - Glaxosmithkline Plc ::‍CONFIRMS IT HAS WITHDRAWN FROM PROCESS RELATING TO PFIZER'S CONSUMER HEALTHCARE BUSINESS​.  Full Article

Pfizer Says Continues To Evaluate Potential Strategic Alternatives For Consumer Healthcare Business
Wednesday, 21 Mar 2018 05:41pm EDT 

March 21 (Reuters) - Pfizer Inc ::PFIZER - CONTINUES TO EVALUATE POTENTIAL STRATEGIC ALTERNATIVES FOR CONSUMER HEALTHCARE BUSINESS.PFIZER - POTENTIAL ALTERNATIVES FOR CONSUMER HEALTHCARE BUSINESS,INCLUDE SPIN-OFF,SALE OR OTHER TRANSACTION,AND PFIZER ULTIMATELY RETAINING BUSINESS.  Full Article

Bioduro Collaboration With Pfizer Leads To Formation of Shelf-Stable Fluorosulfation Reagent‍​
Monday, 19 Mar 2018 07:00am EDT 

March 19 (Reuters) - Bioduro ‍​:BIODURO COLLABORATION WITH PFIZER INC. LEADS TO CREATION OF A SHELF-STABLE FLUOROSULFATION REAGENT.‍BIODURO - CREATION OF AISF, A SHELF-STABLE, CRYSTALLINE REAGENT FOR SYNTHESIS OF FLUOROSULFATES AND SULFAMOYL FLUORIDES​.‍BIODURO SAYS AISF WAS DEVELOPED THROUGH A RESEARCH COLLABORATION WITH PFIZER INC​.  Full Article

Cytomx Therapeutics Provides Operational Update
Wednesday, 7 Mar 2018 04:30pm EST 

March 7 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE.CYTOMX THERAPEUTICS INC - COMPANY EXPECTS ITS EXISTING CAPITAL RESOURCES WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2020.CYTOMX THERAPEUTICS - ON MARCH 6, CO RECEIVED NOTIFICATION OF PFIZER'S INTENT TO TERMINATE THEIR 2013 RESEARCH COLLABORATION, OPTION, LICENSE AGREEMENT.CYTOMX THERAPEUTICS INC - NONE OF PROGRAMS IN PFIZER COLLABORATION HAD ADVANCED TO CLINICAL CANDIDATE STAGE.  Full Article

Pfizer Adds Dan Littman To Its Board
Monday, 5 Mar 2018 03:00pm EST 

March 5 (Reuters) - Pfizer Inc ::DAN R. LITTMAN ELECTED TO PFIZER’S BOARD OF DIRECTORS.‍LITTMAN WAS ALSO APPOINTED TO CORPORATE GOVERNANCE AND SCIENCE AND TECHNOLOGY COMMITTEES OF PFIZER'S BOARD​.  Full Article

Photo

FDA declines to approve Pfizer biosimilar of Roche's cancer drug

Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.